NETAG issues appraisal on Aflibercept (Eylea®) for AMD but defers recommendation

Source: NETAG
Area: Evidence > Drug Specific Reviews
The NHS North East Treatment Advisory Group (NETAG) has issued an appraisal report on aflibercept (Eylea®) for age-related macular degeneration (AMD) but deferred making a recommendation until confirmation of the relevant health economic parameters.

Full Story →